Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Cidofovir (also known as HPMPC; GS-0504; HPMPC; (S)-HPMPC; Vistide) is a potent and injectable antiviral medication approved for the treatment of cytomegalovirus (CMV) retinitis with IC50 of 0.94 μM. It is frequently used to treat AIDS patients' cytomegalovirus (CMV) retinitis. In cultured cells, cidofovir prevents human cytomegalovirus (HCMV) infection. Even when added to the cells 48 hours after infection, cidofovir inhibits the formation of CMV plaques, with an IC50 of 0.9 μg/mL for the Davis strain and 1.6 μg/mL for the AD-169 strain, respectively.
ln Vitro |
|
|
---|---|---|
ln Vivo |
|
|
Cell Assay |
Cell Line: Crandell-Reese feline kidney(CRFK) cells
Concentration: 10-100 μM Incubation Time: 72 hours Result: Reduced CRFK cells by 9.1%. |
|
Animal Protocol |
Female weanling BALB/c mice infected with cowpox virus (CPV)
100 mg/kg Subcutaneous injection; 3-6 days interval; 21 days |
|
References |
Molecular Formula |
C8H14N3O6P
|
|
---|---|---|
Molecular Weight |
279.19
|
|
Exact Mass |
279.06
|
|
Elemental Analysis |
C, 34.42; H, 5.05; N, 15.05; O, 34.38; P, 11.09
|
|
CAS # |
113852-37-2
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
|
|
InChi Key |
VWFCHDSQECPREK-LURJTMIESA-N
|
|
InChi Code |
InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
|
|
Chemical Name |
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5818 mL | 17.9090 mL | 35.8179 mL | |
5 mM | 0.7164 mL | 3.5818 mL | 7.1636 mL | |
10 mM | 0.3582 mL | 1.7909 mL | 3.5818 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01295645 | Active Recruiting |
Drug: Cidofovir Other: No Cidofovir |
Transplantation Infection | M.D. Anderson Cancer Center | March 17, 2011 | Phase 2 |
NCT00000799 | Completed | Drug: Cidofovir Drug: Probenecid |
Cytomegalovirus Retinitis HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
April 1996 | Not Applicable |
NCT00550589 | Completed | Drug: cidofovir Procedure: biopsy |
Precancerous Condition Anal Cancer |
AIDS Malignancy Consortium | September 2007 | Phase 2 |
NCT00001126 | Completed | Drug: Cidofovir | Papilloma | National Institute of Allergy and Infectious Diseases (NIAID) |
November 2005 | Phase 1 |
NCT02931539 | Completed | Drug: Maribavir Drug: Ganciclovir |
Cytomegalovirus (CMV) | Shire | December 22, 2016 | Phase 3 |